Cationic liposome-mediated transfection

Purpose: Existing polynucleotide delivery methods—calcium phosphate, DEAE-dextran, electroporation, retroviral vectors—had limitations in convenience, reproducibility, efficiency, and applicability across cell types. A simple, broadly effective cationic liposome reagent was needed for DNA and RNA transfection of mammalian cells, including suspension cells and hybridomas.

Hypothesis: As a product review, there is no formal experimental hypothesis. Central working model: if DOTMA/DOPE cationic liposomes are mixed with DNA or RNA, then they spontaneously form net-positive nucleic acid–liposome complexes that fuse with negatively charged cell membranes and deliver functional polynucleotides into mammalian cells with high efficiency.

Aims: Describe the DOTMA cationic liposome reagent and its postulated mechanism of action. - Explain the importance of DOTMA-to-DNA ratio, complex size, and charge for transfection. - Summarise applications and comparative performance versus calcium phosphate, DEAE-dextran, and other methods. - Highlight advantages, limitations, and future potential, including possible in vivo therapeutic applications.

Delivery system: Cationic lipid: DOTMA, \([N]\)-1-(2,3-dioleyloxy)propyl-\(N,N,N\)-triethylammonium. - Formulation: sonicated unilamellar vesicles containing equal parts DOTMA and dioleoylphosphatidylethanolamine (DOPE) in water. - Payloads: plasmid DNA, double-stranded RNA, single-stranded mRNA, in vitro-transcribed infectious RNA, and large DNA molecules such as 130-kb baculovirus DNA. - Complex: DNA/DOTMA complexes form spontaneously; nucleic acid is trapped in the complex interior. No targeting ligand. - Commercial product: Lipofectin.

Approach: Product review/methods description. In vitro mammalian cell systems include mouse L-cell fibroblasts, PC12 cells, suspension cells, hybridomas, over 50 cell lines, and primary cell cultures. No in vivo model. The review compares DOTMA reagent with calcium phosphate, DEAE-dextran, electroporation, and retroviral methods. Not a systematic review or primary experimental study.

Key methods: Laser light scattering for complex size; rhodamine-labelled lipid and fluorescent DNA for cell-surface fusion/uptake; radioactive labelling for polynucleotide adsorption; nuclear fraction plasmid recovery; histochemical \(\beta\)-galactosidase staining; stable transformation efficiency; transfection with double-stranded RNA; mRNA expression assays.

Key results: DOTMA/DOPE liposomes are approximately 250 nm in diameter and contain about 2,500 lipid molecules; about 1,250 are positively charged DOTMA. - A standard 2,500-bp plasmid has about 5,000 negative charges; approximately four liposomes are needed to neutralise one plasmid. - Cells adsorb 20–80% of added polynucleotide. In a typical experiment with \(2\mu g\) plasmid per million cells, about 500,000 plasmids are expected to be taken up per cell, but only 300 intact psV2-CAT plasmids per cell were recovered in the nuclear fraction—less than 1% reaching the nucleus intact. Calcium phosphate yielded <10 plasmid copies per cell in the nucleus. - \(\beta\)-galactosidase staining: up to 25% of cells positive. Double-stranded RNA experiments indicated >99% of cells were transfected. - Stable transformation efficiencies as high as 10% were obtained, depending on vector and cell type. - In some cell lines, 10- to 100-fold improvements over other methods were demonstrated; the reagent worked in over 50 cell lines and primary cultures. - Transfection is performed in serum-free media; purified sulphated proteoglycans are potent inhibitors. pH between 6.0 and 8.0 has essentially no effect.

Interpretation: DOTMA-mediated transfection is broadly applicable, convenient, reproducible, and efficient across many mammalian cell types for both stable and transient expression. It also enables delivery of mRNA and other polynucleotides, opening new experimental approaches. The authors suggest future cationic liposome delivery systems may eventually be applicable to in vivo polynucleotide therapeutics.

Limitations: This is a product review, not a primary study. Some applications may still favour optimised calcium phosphate or electroporation, especially for certain suspension cultures. The mechanism is partly hypothetical. Transfection requires serum-free conditions and is inhibited by sulphated proteoglycans. No in vivo data, toxicity, or long-term safety data are presented. The supplied text does not include a DOI or full reference list.